BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma W, Ma J, Lei T, Zhao M, Zhang M. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody. J Cancer 2019;10:5153-61. [PMID: 31602268 DOI: 10.7150/jca.29937] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Pan S, Li S, Zhan Y, Chen X, Sun M, Liu X, Wu B, Li Z, Liu B. Immune status for monitoring and treatment of bladder cancer. Front Immunol 2022;13:963877. [DOI: 10.3389/fimmu.2022.963877] [Reference Citation Analysis]
2 Mukherjee AG, Wanjari UR, Namachivayam A, Murali R, Prabakaran DS, Ganesan R, Renu K, Dey A, Vellingiri B, Ramanathan G, Doss C. GP, Gopalakrishnan AV. Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach. Vaccines 2022;10:1493. [DOI: 10.3390/vaccines10091493] [Reference Citation Analysis]
3 Mansorunov D, Apanovich N, Apanovich P, Kipkeeva F, Muzaffarova T, Kuzevanova A, Nikulin M, Malikhova O, Karpukhin A. Expression of Immune Checkpoints in Malignant Tumors: Therapy Targets and Biomarkers for the Gastric Cancer Prognosis. Diagnostics (Basel) 2021;11:2370. [PMID: 34943606 DOI: 10.3390/diagnostics11122370] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
4 Eldh M, Mints M, Hiltbrunner S, Ladjevardi S, Alamdari F, Johansson M, Jakubczyk T, Veerman RE, Winqvist O, Sherif A, Gabrielsson S. Proteomic Profiling of Tissue Exosomes Indicates Continuous Release of Malignant Exosomes in Urinary Bladder Cancer Patients, Even with Pathologically Undetectable Tumour. Cancers (Basel) 2021;13:3242. [PMID: 34209558 DOI: 10.3390/cancers13133242] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
5 Bogen JP, Grzeschik J, Jakobsen J, Bähre A, Hock B, Kolmar H. Treating Bladder Cancer: Engineering of Current and Next Generation Antibody-, Fusion Protein-, mRNA-, Cell- and Viral-Based Therapeutics. Front Oncol 2021;11:672262. [PMID: 34123841 DOI: 10.3389/fonc.2021.672262] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Allegra A, Pioggia G, Innao V, Musolino C, Gangemi S. New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges. Cancers (Basel) 2021;13:1981. [PMID: 33924049 DOI: 10.3390/cancers13081981] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
7 Marcucci F, Rumio C. Depleting Tumor Cells Expressing Immune Checkpoint Ligands-A New Approach to Combat Cancer. Cells 2021;10:872. [PMID: 33921301 DOI: 10.3390/cells10040872] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Liu Y, Wu Y, Zhang P, Xu C, Liu Z, He C, Liu Y, Kang Z. CXCL12 and CD3E as Indicators for Tumor Microenvironment Modulation in Bladder Cancer and Their Correlations With Immune Infiltration and Molecular Subtypes. Front Oncol 2021;11:636870. [PMID: 33747959 DOI: 10.3389/fonc.2021.636870] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
9 Feng R, Li Z, Wang X, Ge G, Jia Y, Wu D, Ji Y, Wang C. Silenced lncRNA SNHG14 restrains the biological behaviors of bladder cancer cells via regulating microRNA-211-3p/ESM1 axis. Cancer Cell Int 2021;21:67. [PMID: 33482820 DOI: 10.1186/s12935-020-01717-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
10 Middelburg J, Kemper K, Engelberts P, Labrijn AF, Schuurman J, van Hall T. Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors. Cancers (Basel) 2021;13:287. [PMID: 33466732 DOI: 10.3390/cancers13020287] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
11 Changing Paradigms in the Treatment of Advanced Urothelial Carcinoma: A 2020 Update. EMJ Oncol 2020. [DOI: 10.33590/emj/20-00044] [Reference Citation Analysis]
12 Zhou X, Chen N, Xu H, Zhou X, Wang J, Fang X, Zhang Y, Li Y, Yang J, Wang X. Regulation of Hippo-YAP signaling by insulin-like growth factor-1 receptor in the tumorigenesis of diffuse large B-cell lymphoma. J Hematol Oncol 2020;13:77. [PMID: 32546241 DOI: 10.1186/s13045-020-00906-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 12.0] [Reference Citation Analysis]